Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-63.06	-41.52	-59.69	-58.39	-42.85
Depreciation & Amortization	0.11	0.65	0.6	0.48	0.36
Other Amortization	0.43	0.37	0.24	-	-
Loss (Gain) From Sale of Assets	-	0.01	-	0.14	-
Loss (Gain) From Sale of Investments	-0.08	-0.45	-0.16	-0.1	-
Stock-Based Compensation	7.46	5.78	9.53	9.05	7.28
Other Operating Activities	3.41	2.67	1.8	-0.39	-0.27
Change in Accounts Receivable	-0.16	1.72	-2.33	-0.76	0.1
Change in Inventory	-0.65	-	-	-	-
Change in Accounts Payable	4.43	0.88	1.04	-0.91	0.64
Change in Other Net Operating Assets	-0.94	1.06	2.53	-1.6	1.52
Operating Cash Flow	-49.04	-28.85	-46.42	-52.47	-33.22
Capital Expenditures	-0.3	-0.03	-0.11	-0.27	-
Investment in Securities	11.55	8.32	4.87	-56.85	70
Investing Cash Flow	11.25	8.28	4.76	-57.12	70
Long-Term Debt Issued	-	-	50	-	-
Net Debt Issued (Repaid)	-	-	50	-	-
Issuance of Common Stock	82.95	27.5	0.58	3.09	0.12
Other Financing Activities	2.57	4.62	-2.79	-	4.93
Financing Cash Flow	85.53	32.12	47.79	3.09	5.06
Net Cash Flow	47.73	11.55	6.12	-106.51	41.83
Free Cash Flow	-49.34	-28.88	-46.54	-52.74	-33.22
Free Cash Flow Margin	-3191.66%	-	-4653.60%	-1054.82%	-221.49%
Free Cash Flow Per Share	-0.59	-0.46	-1.08	-1.24	-0.79
Levered Free Cash Flow	-36.95	-18.12	-28.29	-31.36	-17.05
Unlevered Free Cash Flow	-34.98	-16.25	-26.94	-31.36	-17.05
Change in Working Capital	2.68	3.66	1.24	-3.26	2.26

Updated Mar 20, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q